RESEARCH TRIANGLE PARK, N.C., USA, March 31, 2026
AskBio, a wholly owned and independently operated subsidiary of Bayer AG, has announced the successful completion of patient enrollment in its Phase 2 GenePHIT clinical trial evaluating AB-1002, an investigational AAV-based gene therapy for congestive heart failure (CHF). This milestone marks a significant advancement in the clinical development of next-generation gene therapies targeting cardiovascular diseases, bringing the program closer to key efficacy readouts and potential late-stage development.
Phase 2 Enrollment Completion Signals Clinical Progress
The GenePHIT Phase 2 clinical trial is a randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the safety and efficacy of AB-1002 in patients with New York Heart Association (NYHA) Class III heart failure. The completion of enrollment represents a critical milestone, enabling the study to move forward toward topline data analysis and potential progression to Phase 3 trials.
AB-1002 is a one-time, investigational gene therapy administered via intracoronary infusion, delivering a functional gene designed to improve cardiac function at the molecular level. Unlike traditional therapies that primarily manage symptoms, this approach aims to address the underlying biological mechanisms of heart failure, offering the potential for long-term disease modification.
The trial builds on encouraging findings from earlier studies, including Phase 1 clinical data that demonstrated improvements in cardiac biomarkers, functional capacity, and quality of life measures, supporting continued development of the therapy. The completion of enrollment also reflects strong clinical site engagement and patient participation across multiple regions, reinforcing the growing interest in gene therapy approaches for cardiovascular conditions.
Advertisement
Gene Therapy Innovation Targets Unmet Needs in Heart Failure
Heart failure remains a leading cause of morbidity and mortality worldwide, affecting more than 64 million people globally, with limited options for patients in advanced stages of the disease. Current standard-of-care treatments, including pharmacological therapies and device-based interventions, often focus on symptom management rather than reversing disease progression.
AB-1002 utilizes an adeno-associated virus (AAV) vector platform to deliver a gene encoding SERCA2a (sarcoplasmic reticulum calcium ATPase), a critical protein involved in regulating cardiac muscle contraction and relaxation. Reduced expression of SERCA2a is a hallmark of heart failure, contributing to impaired cardiac function and disease progression. By restoring SERCA2a levels, AB-1002 aims to improve cardiac performance and patient outcomes.
This innovative approach positions AB-1002 within a new class of disease-modifying therapies, potentially transforming the treatment landscape for patients with severe heart failure. The therapy has also received FDA Fast Track designation, highlighting its potential to address significant unmet medical needs and accelerate regulatory development pathways.
Regulatory Outlook and Future Development Pathway
With enrollment now complete, the GenePHIT study will focus on monitoring patient outcomes, collecting safety data, and evaluating clinical endpoints, which will be critical in determining the therapy’s future trajectory. Positive results could support advancement into Phase 3 trials and eventual regulatory submissions, paving the way for potential commercialization.
AskBio’s progress reflects the broader momentum in gene therapy innovation, particularly in expanding applications beyond rare genetic disorders into chronic and complex diseases such as cardiovascular conditions. As part of Bayer’s global strategy, the company is leveraging its expertise in AAV gene therapy platforms, clinical development, and regulatory engagement to accelerate the delivery of transformative treatments.
The successful execution of the Phase 2 trial also highlights the importance of robust clinical trial infrastructure and regulatory compliance (GCP standards) in advancing cutting-edge therapies. As gene therapy continues to evolve, it is expected to play an increasingly central role in precision medicine and personalized treatment approaches.
Advancing Gene Therapy in Cardiovascular Medicine
The completion of enrollment in the Phase 2 GenePHIT trial marks a key milestone in the development of AB-1002, bringing the therapy closer to potential regulatory approval and clinical use. With its innovative mechanism and disease-modifying potential, AB-1002 represents a promising step forward in addressing the global burden of heart failure and advancing the future of cardiovascular gene therapy.
Source: AskBio press release
